B&J Biopharma
B&J Biopharma develops AI-driven anti-cancer therapies that target tumor heterogeneity to overcome drug resistance. The company uses machine learning models trained on tumor variety and genomic data to identify and design novel small molecules and biologics that address intratumoral diversity. B&J operates as a B2B biotech therapeutics developer partnering with research institutions and pharmaceutical companies to advance candidates through preclinical and clinical stages. Core technologies include AI/ML, genomics-driven target identification, and computational drug design. The company addresses the large oncology market by focusing on resistant cancers and candidates intended for clinical development and commercialization.
B&J Biopharma
B&J Biopharma develops AI-driven anti-cancer therapies that target tumor heterogeneity to overcome drug resistance. The company uses machine learning models trained on tumor variety and genomic data to identify and design novel small molecules and biologics that address intratumoral diversity. B&J operates as a B2B biotech therapeutics developer partnering with research institutions and pharmaceutical companies to advance candidates through preclinical and clinical stages. Core technologies include AI/ML, genomics-driven target identification, and computational drug design. The company addresses the large oncology market by focusing on resistant cancers and candidates intended for clinical development and commercialization.